Pharma Stocks
-
Neuren Pharmaceuticals Rises as Biotech Confidence Builds Again
Key Highlights: • Neuren Pharmaceuticals develops therapies for neurological and neurodevelopmental disorders. • Improving sentiment across the biotech sector has…
Read More » -
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused…
Read More » -
Is Alnylam Pharmaceuticals (ALNY) Undervalued Following Its Expanded Komodo Health AI Partnership?
Alnylam expands AI partnership with Komodo Health Alnylam Pharmaceuticals (ALNY) has expanded its collaboration with Komodo Health, extending use of…
Read More » -
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here’s Why the Trend Could be Sustainable
Most of us have heard the dictum “the trend is your friend.” And this is undeniably the key to success…
Read More » -
Nifty 50 Rises 39 Points as Pharma and Healthcare Stocks Outperform
The Nifty 50 gained 38.95 points, or 0.16 per cent, to 24,094.95, while the Sensex advanced 77.06 points, or 0.10…
Read More » -
Does Royalty Pharma’s (RPRX) Index Upgrade Signal Deeper Defensive Strength In Its Business Model?
Royalty Pharma plc (NasdaqGS:RPRX) was recently added to both the Russell 1000 Defensive Index and the Russell 1000 Value-Defensive Index,…
Read More » -
5 Best Low-Priced Pharma Stocks to Buy Right Now
When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off…
Read More » -
Nuvectis Pharma Up 97%, Insider Buyers Are Up 344%
Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose…
Read More » -
Moderna Stock and Healthcare Names Facing the Biggest Regulatory Calls
Healthcare regulation is back in focus, and sudden shifts in approvals, safety reviews, and policy debates are putting a spotlight…
Read More » -
Johnson & Johnson (JNJ) Stock After 71% One-Year Rally And Pharma Pipeline Focus
If you are wondering whether Johnson & Johnson stock still offers value after a strong run, this article breaks down…
Read More »